JNJ Research Update — April 20, 2026
Updated Thesis
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period, reflecting operational strength.
The investment grade as of this refresh is C — average business quality. High-tier business, expensive valuation with 14% upside to $263.05 fair value
Key Metrics at a Glance
- Revenue growth: +9.9% year over year
- Net margin: 21.8%
- Forward P/E: 26.8x
- Fair value upside: +14.0% to our estimate of $263
Current price: $230.69
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Johnson & Johnson remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full JNJ research →](/stocks/JNJ)